Abstract
Heart rate variability (HRV) is the fluctuation in the time interval between consecutive heartbeats, the measurement of which is a non-invasive method for assessing the autonomic status. The autonomic nervous system plays an important role in physiological situations, and in various pathological processes such as in cardiovascular diseases and viral infections. This study examined the cardiac autonomic responses, as measured by HRV before, after, and during coronavirus disease. In this study, we used beat interval data extracted from the Welltory app from 14 eligible subjects (9 men and 5 women) with a mean age (SD) of 44 (8.7) years. HRV analysis was performed through an assessment of time-domain indices (SDNN and RMSSD). Group analysis did not reveal any statistical difference between HRV metrics before, during, and after COVID-19. However, HRV at the individual level showed a statistically significant individual change during COVID-19 in some users. These data further support the usefulness of using individual-level HRV tracking for the detection of early diseases inclusive of COVID-19.
Competing Interest Statement
The authors of this study have paid consulting agreements with Welltory Inc. The company that provided the data for this study is an interested party relevant to the results of this research. Special official confirmation was obtained from the company, which confirms that the data provided fully matches the description of the data and were not specially selected in any way other than in accordance with the selection criteria described in this publication. The company confirmed that necessary user consent was obtained for the purposes of this study.
Clinical Trial
The study is retrospective. We utilized already existing data.
Funding Statement
This work was supported by Welltory Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been determined by the Pearl Institutional Review Board to be Exempt according to FDA 21 CFR 56.104 and 45CFR46.104(b)(4): (4) Secondary Research Uses of Data or Specimens on 05/21/2021.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data is not available.
Abbreviations
- ANS
- autonomic nervous system
- COVID-19
- coronavirus disease 2019
- cPNA
- cardiac parasympathetic nervous activity
- cSNA
- cardiac sympathetic nervous activity
- ECG
- electrocardiogram
- HR
- heart rate
- HRV
- heart rate variability
- PPG
- photoplethysmography
- RHR
- resting heart rate
- RR
- respiration rate
- RMSSD
- root mean square of successive normal-to-normal interval differences
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- SDNN
- standard deviation of normal-to-normal intervals
